OVARIAN HYPERSTIMULATION SYNDROME: PATIENT MANAGEMENT TACTICS, PREVENTION (PART 2)


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The objective of the study was to acquaint clinicians with the current status of a problem in the diagnosis and treatment of ovarian hyperstimulation syndrome (OHSS). Part 2 of the article discusses the possibilities of inpatient treatment, indications for hospitalization, the major task of inpatient treatment, as well as issues in the organization of medical care to these patients. It presents current methods for preventing OHSS in the context of evidence-based medicine.

全文:

受限制的访问

作者简介

I. KORNEEVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: irina.korneeva@inbox.ru
Moscow

T. SAROYAN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Moscow

E. KALININA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Moscow

V. SMOLNIKOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Moscow

参考

  1. Royal College of Obstetricians and Gynaecologists. The management of ovarian hyperstimulation syndrome. 2006. http:// www.rcog.org.uk/files/rcog-corp/GTG5_230611.pdf.
  2. Avecillas J.F., Falcone T., Arroliga A.C. Ovarian hyperstimulation syndrome. Crit. Care Clin. 2004; 20(4): 679—95; ix.
  3. Budev M.M., Arroliga A.C., Falcone T. Ovarian hyperstimulation syndrome. Crit. Care Med. 2005; 3 (10, Suppl.): S301—6.
  4. Корнеева И.Е., Веряева Н.А. Комплексная терапия при синдроме гиперстимуляции яичников. Врач. 2006; 9: 54—6.
  5. Gamzu R., Almog B., Levin Y., Avni A., Lessing J.B., Baram A. Efficacy of hydroxyethyl starch and haemaccel for the treatment of severe ovarian hyperstimulation syndrome. Fertil. Steril. 2002; 77(6): 1302—3.
  6. Feng X., Yan W., Liu X., Duan M., Zhang X., Xu J. Effects of hydroxyethyl starch 130/0.4 on pulmonary capillary leakage and cytokines production and NF-kappaB activation in CLP-induced sepsis in rats. J. Surg. Res. 2006; 135 (1): 129—36.
  7. Van der Linden P.J., De Hert S.G., Deraedt D., Cromheecke S., De Decker K., De Paep R. et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth. Analg. 2005; 101(3): 629—34.
  8. Hoffmann J.N., Vollmar B., Laschke M.W., Inthorn D., Schildberg F.W., Menger M.D. Hydroxyethyl starch (130 kD), but not crystalloid volume support, improves microcirculation during normotensive endotoxemia. Anesthesiology. 2002; 97(2): 460—70.
  9. Корнеева И.Е., Назаренко Т.А., Аксененко А.А., Соколова М.Ю. Нарушение функции печени у пациентки с синдромом гиперстимуляции яичников. Проблемы репродукции. 2009; 15(3): 70—3.
  10. Bellver J., Munoz E.A., Ballesteros A., Soares S.R., Bosch E., Simon C. et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum. Reprod. 2003; 18(11): 2283—8.
  11. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. Br. Med. J. 1998; 317(7153): 235—40.
  12. Ferraretti A.P., Gianaroli L., Diotallevi L., Festi C., Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum. Reprod. 1992; 7(2): 180—3.
  13. Bellomo R., Chapman M., Finfer S., Hickling K., Myburgh J., Belessis A. et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet. 2000; 356(9248): 2139—43.
  14. Корнеева И.Е., Фанченко Н.Д., Иванова А.В., Иванец Т.Ю. Определение фактора Виллебранда с целью прогнозирования тяжести синдрома гиперстимуляции яичников. В кн.: Материалы XIV международной конференции Российской Ассоциации Репродукции Человека «Репродуктивные технологии сегодня и завтра». Москва, 26-28 сентября 2004 г. М.; 2004: 93—4.
  15. Boldt J., Haisch G., Suttner S., Kumle B., Schellhaass A. Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend) on measures of coagulation. Br. J. Anaesth. 2002; 89(5): 722—8.
  16. Ickx B.E., Bepperling F., Melot C., Schulman C., Van der Linden P.J. Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 during and after extended acute normovolaemic haemodilution. Br. J. Anaesth. 2003; 91(2): 196—202.
  17. Сароян Т.Т., Корнеева И.Е. Тактика ведения индуцированной беременности, наступившей на фоне тяжелого течения синдрома гиперстимуляции яичников. Акушерство и гинекология. 2011; 8: 107—11.
  18. Корнеева И.Е., Камилова Д.П., Фанченко Н.Д., Иванец Т.Ю., Леонов Б.В. Профилактика тромбоэмболических осложнений у пациенток с синдромом гиперстимуляции яичников. Проблемы репродукции. 2002; 8(2): 30—3.
  19. Сароян Т.Т. Особенности течения беременности у женщин с тяжелой формой синдрома гиперстимуляции яичников: Автореф. дис.. канд. мед. наук. М.; 2009. 25с.
  20. Ставничук А.В. Профилактика тромбоэмболических осложнений у женщин с синдромом гиперстимуляции яичников: Автореф. дис. канд. мед. наук. M.; 2009. 24с.
  21. Abuzeid M.I., Nassar Z., Massaad Z., Weiss M., Ashraf M., Fakih M. Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum. Reprod. 2003; 18(2): 370—3.
  22. Ferraretti A.P., Goossens V., de Mouzon J., Bhattacharya S., Castilla J.A., Korsak V. et al. Assisted reproductive technology in Europe, 2008: results generated from European registers by ESHRE. Hum. Reprod. 2012; 27(9): 2571—84.
  23. Humaidan P., Quartarolo J., Papanikolaou E.G. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil. Steril. 2010; 94(2): 389—400.
  24. Peng C., Fan N.C., Ligier M., Vaananen J., Leung P.C. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology. 1994; 135(5): 1740—6.
  25. Weiss J.M., Oltmanns K., Gurke E.M., Polack S., Eick F., Felberbaum R. et al. Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. Eur. J. Endocrinol. 2001; 144(6): 677—85.
  26. Asimakopoulos B., Nikolettos N., Nehls B., Diedrich K., Al-Hasani S., Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil. Steril. 2006; 86(3): 636—41.
  27. Youssef M.A., Al-Inany H.G., Evers J.L., Aboulghar M. Intravenous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst. Rev. 2011 (2): CD001302.
  28. Youssef M.A., Van der Veen F., Al-Inany H.G., Griesinger G., Mochtar M.H., Aboulfoutouh I. et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst. Rev. 2011 (1): CD008046.
  29. Humaidan P. Agonist trigger: what is the best approach? Agonist trigger and low dose hCG. Fertil. Steril. 2012; 97(3): 529—30.
  30. Shapiro B.S., Daneshmand S.T., Garner F.C., Aguirre M., Hudson C. Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil. Steril. 2011; 95(8): 2715—7.
  31. Radesic B., Tremellen K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum. Reprod. 2011; 26(12): 3437—42.
  32. Youssef M.A., van Wely M., Hassan M.A., Al-Inany H.G., Mochtar M., Khattab S. et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum. Reprod. Update. 2010; 16(5): 459—66.
  33. Acevedo B., Gomez-Palomares J.L., Ricciarelli E., Hernandez E.R. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil. Steril. 2006; 86(6): 1682—7.
  34. Melo M., Busso C.E., Bellver J., Alama P., Garrido N., Meseguer M. et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod. Biomed. Online. 2009; 19(4): 486—92.
  35. Manzanares M.A., Gomez-Palomares J.L., Ricciarelli E., Hernandez E.R. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil. Steril. 2010; 93(4): 1215—9.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##